Publicaties

Binnen de onderzoeksgroep van het ErasMS worden regelmatig bevindingen gepubliceerd in wetenschappelijke tijdschriften. Ook worden voordrachten gehouden over onderzoeksbevindingen bijvoorbeeld (internationale) congressen

PUBLICATIES 2024
1. Hoeks C, Puijfelik FV, Koetzier SC, Rip J, Corsten CEA, Wierenga-Wolf AF, Melief MJ, Stinissen P, Smolders J, Hellings N, Broux B, van Luijn MM. Differential Runx3, Eomes, and T-bet expression subdivides MS-associated CD4+ T cells with brain-homing capacity. Eur J Immunol. 2024 Feb;54(2):e2350544. https://onlinelibrary.wiley.com/doi/10.1002/eji.202350544
2.  van den Bosch AMR, van der Poel M, Fransen NL, Vincenten MCJ, Bobeldijk AM, Jongejan A, Engelenburg HJ, Moerland PD, Smolders J, Huitinga I, Hamann J. Profiling of microglia nodules in multiple sclerosis reveals propensity for lesion formation. Nat Commun. 2024 Feb 23;15(1):1667. doi: 10.1038/s41467-024-46068-3. https://www.nature.com/articles/s41467-024-46068-3
3. van Puijfelik F, Blok KM, Klein Kranenbarg RAM, Rip J, de Beukelaar J, Wierenga-Wolf AF, Wokke B, van Luijn MM, Smolders J. Ocrelizumab associates with reduced cerebrospinal fluid B and CD20dim CD4+ T cells in primary progressive multiple sclerosis. Brain Commun. 2024 Jan 29;6(1):fcae021. https://academic.oup.com/braincomms/article/6/1/fcae021/7591528
4.  Ingelfinger F, Kuiper KL, Ulutekin C, Rindlisbacher L, Mundt S, Gerdes LA, Smolders J, van Luijn MM, Becher B. Twin Study dissects CXCR3+ memory B cells as non-heritable feature in multiple sclerosis. Med 2024. In press.
PUBLICATIES 2023
1. Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, Ramanathan S, Waters P, Tenembaum S, Graves JS, Chitnis T, Brandt AU, Hemingway C, Neuteboom R, Pandit L, Reindl M, Saiz A, Sato DK, Rostasy K, Paul F, Pittock SJ, Fujihara K, Palace J. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023 Jan 24:S1474-4422(22)00431-8. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00431-8/fulltext.
2. Blok KM, van Rosmalen J, Tebayna N, Smolders J, Wokke B, de Beukelaar J. Disease activity in primary progressive multiple sclerosis: a systematic review and meta-analysis. Front Neurol. 2023 Nov 6;14:1277477. doi: 10.3389/fneur.2023.1277477. eCollection 2023. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2023.1277477/full
3. Blok KM, Smolders J, van Rosmalen J, Martins Jarnalo CO, Wokke B, de Beukelaar J. Real-world challenges in the diagnosis of primary progressive multiple sclerosis. Eur J Neurol. 2023 Dec;30(12):3799-3808. doi: 10.1111/ene.16042. Epub 2023 Sep 15. https://onlinelibrary.wiley.com/doi/10.1111/ene.16042
4. Bogers L, Engelenburg HJ, Janssen M, Unger PP, Melief MJ, Wierenga-Wolf AF, Hsiao CC, Mason MRJ, Hamann J, van Langelaar J, Smolders J, van Luijn MM. Selective emergence of antibody-secreting cells in the multiple sclerosis brain. eBioMedicine 2023;89:104465. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(23)00030-0/fulltext.
5. Bogers L, Kuiper KL, Smolders J, Rip J, van Luijn MM. Epstein-Barr virus and genetic risk variants as determinants of T-bet+ B cell-driven autoimmune diseases. Immunol Lett. 2023 Sep;261:66-74. doi: 10.1016/j.imlet.2023.07.006. https://www.sciencedirect.com/science/article/pii/S0165247823001189?via%3Dihub
6. van den Bosch AMR, Hümmert S, Steyer A, Ruhwedel T, Hamann J, Smolders J, Nave KA, Stadelmann C, Kole MHP, Möbius W, Huitinga I. Ultrastructural Axon-Myelin Unit Alterations in Multiple Sclerosis Correlate with Inflammation. Ann Neurol. 2023;83:856-870. https://onlinelibrary.wiley.com/doi/10.1002/ana.26585
7. Brenner J, Mariotto S, Bastiaansen AEM, Paunovic M, Ferrari S, Alberti D, de Bruijn MAAM, Crijnen YS, Schreurs MWJ, Neuteboom RF, Damoiseaux JGMC, de Vries JM, Titulaer MJ. Predictive Value of Serum Neurofilament Light Chain Levels in Anti-NMDA Receptor Encephalitis. Neurology. 2023 Apr 4:10.1212/WNL.0000000000207221. https://n.neurology.org/content/early/2023/04/03/WNL.0000000000207221.long
8. Bruijstens AL, Stingl C, Güzel C, Stoop MP, Wong YYM, van Pelt ED, Banwell BL, Bar-Or A, Luider TM, Neuteboom RF; Dutch Pediatric MS and ADEM Study Group; Canadian Pediatric Demyelinating Disease Network. Neurodegeneration and humoral response proteins in cerebrospinal fluid associate with pediatric-onset multiple sclerosis and not monophasic demyelinating syndromes in childhood. Mult Scler. 2023 Jan;29(1):52-62. https://journals.sagepub.com/doi/full/10.1177/13524585221125369
9. Corsten CEA, Huygens SA, Versteegh MM, Wokke BHA, Smets I, Smolders J. Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model. Mult Scler Relat Disord. 2023 Dec;80:105100. doi: 10.1016/j.msard.2023.105100. Epub 2023 Oct 22. https://linkinghub.elsevier.com/retrieve/pii/S2211-0348(23)00601-6
10. Ghezzi A, Neuteboom RF. The contribution of neurofilament light chain to better characterize pediatric multiple sclerosis (editorial on: Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial). Mult Scler. 2023 Mar 23;13524585231161148. https://journals.sagepub.com/doi/10.1177/13524585231161148?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
11. Hsiao CC, Engelenburg HJ, Jongejan A, Zhu J, Zhang B, Mingueneau M, Moerland PD, Huitinga I, Smolders J, Hamann J. Osteopontin associates with brain TRM-cell transcriptome and compartmentalization in donors with and without multiple sclerosis. iScience. 2022 Dec 9;26(1):105785. https://www.cell.com/iscience/fulltext/S2589-0042(22)02058-2
12. International Multiple Sclerosis Genetics Consortium; MultipleMS Consortium. Locus for severity implicates CNS resilience in progression of multiple sclerosis. Nature. 2023 Jul;619(7969):323-331. doi: 10.1038/s41586-023-06250-x. Epub 2023 Jun 28. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602210/
13. de Mol CL, van Luijn MM, Kreft KL, Looman KIM, van Zelm MC, White T, Moll HA, Smolders J, Neuteboom RF. Multiple sclerosis risk variants influence the peripheral B-cell compartment early in life in the general population. Eur J Neurol. 2023 Feb;30(2):434-442. https://onlinelibrary.wiley.com/doi/10.1111/ene.15582.
14. Neuteboom R. Real world data on treatment of pediatric onset multiple sclerosis. Eur J Paediatr Neurol. 2023 Jul;45:A1. doi: 10.1016/j.ejpn.2023.06.011. Epub 2023 Jun 30. https://linkinghub.elsevier.com/retrieve/pii/S1090-3798(23)00101-0
15. Ombashi S, Tsangaris E, Heeres AG, van Roey V, Neuteboom RF, van Veelen-Vincent MLC, Jansson K, Mathijssen IMJ, Klassen AF, Versnel SL. Quality of life in children suffering from headaches: a systematic literature review. J Headache Pain. 2023 Sep 18;24(1):127. doi: 10.1186/s10194-023-01595-0 https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-023-01595-0
16. Smets I, Wokke B, Smolders J. Should anti-CD20 be used as an immune reconstitution therapy? Mult Scler. 2023 Feb;29(2):308-310. https://journals.sagepub.com/doi/full/10.1177/13524585221109386.
17. Smets I, Versteegh M, Huygens S, Corsten C, Wokke B, Smolders J. Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model. Mult Scler J Exp Transl Clin. 2023 Jul 24;9(3):20552173231189398. doi: 10.1177/20552173231189398 https://journals.sagepub.com/doi/10.1177/20552173231189398
18. Smets I. Presymptomatic MS or radiologically isolated syndrome (RIS) should be actively monitored and treated – NO. Multiple Sclerosis Journal 2023;29(7):795-797. https://journals.sagepub.com/doi/10.1177/13524585231172945
19. Smolders J. NAAR EEN OPTIMALE INZET VAN VEELZIJDIGE ANTI-CD20-THERAPIE BIJ NEUROLOGISCHE ZIEKTEBEELDEN. TIJDSCHR NEUROL NEUROCHIR 2023;124(7):285–6. https://www.tnnonline.nl/journal-article/naar-een-optimale-inzet-van-veelzijdige-anti-cd20-therapie-bij-neurologische-ziektebeelden/
20. Smolders J, Steelman AJ, Inoue M. Editorial: Environmental factors influencing the immune functions during multiple sclerosis. Front Immunol. 2023 Jan 20;14:1141014. https://www.frontiersin.org/articles/10.3389/fimmu.2023.1141014/full.
21. Smolders J, Damoiseaux J. Considerations on vitamin D supplementation in multiple sclerosis, 1 Jan 2023, Vitamins and Minerals in Neurological Disorders. Martin, C. R., Patel, V. B. & Preedy, V. R. (eds.). 1 ed. Elsevier Inc., p. 359-377 19 p. https://www.sciencedirect.com/science/article/abs/pii/B9780323898355000120?via%3Dihub
22. Van Steenhoven RW, de Vries JM, Bruijstens AL, Paunovic M, Nagtzaam MM, Franken SC, Bastiaansen AE, De Bruijn MA, Van Sonderen A, Schreurs MWJ, Gardeniers M, Verdijk RM, Balvers RK, Sillevis Smitt PA, Neuteboom RF, Titulaer MJ. Mimics of Autoimmune Encephalitis: Validation of the 2016 Clinical Autoimmune Encephalitis Criteria. Neurol Neuroimmunol Neuroinflamm. 2023 Aug 15;10(6):e200148. doi: 10.1212/NXI.0000000000200148. Print 2023 Nov. https://www.neurology.org/doi/10.1212/NXI.0000000000200148
23. Toorop AA, van Kempen ZLE, Steenhuis M, Nielsen J, Sinnige LGF, van Dijk G, Roosendaal CM, Arnoldus EPJ, Hoitsma E, Lissenberg-Witte BI, de Jong BA, Oosten BWV, Strijbis EMM, Uitdehaag BMJ, Rispens T, Killestein J; NEXT-MS study group. Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2023 Jun;94(6):482-486. doi: 10.1136/jnnp-2022-330467. Epub 2023 Jan 13. https://jnnp.bmj.com/content/94/6/482
24. Toorop AA, van Lierop ZY, Gelissen LM, Hoitsma E, Zeinstra EM, van Rooij LC, van Munster CE, Vennegoor A, Mostert JP, Wokke BH, Kalkers NF, Hoogervorst EL, van Eijk JJ, Roosendaal CM, Kragt JJ, Eurelings M, van Genugten J, Nielsen J, Sinnige L, Kloosterziel ME, Arnoldus EP, van Dijk GW, Bouvy WH, Wessels MH, Boonkamp L, Strijbis EM, van Oosten BW, De Jong BA, Lissenberg-Witte BI, Barkhof F, Moraal B, Teunissen CE, Rispens T, Uitdehaag BM, Killestein J, van Kempen ZL. Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS). J Neurol Neurosurg Psychiatry. 2023 Nov 14:jnnp-2023-332119. doi: 10.1136/jnnp-2023-332119. https://jnnp.bmj.com/content/early/2023/11/13/jnnp-2023-332119
25. Willekens BMP, Kleffner I, Wokke B. Editorial: Epidemiology, diagnosis, prognosis and treatment of rare immune-mediated diseases of the central nervous system. Front Neurol. 2023 Dec 13;14:1342817. doi: 10.3389/fneur.2023.1342817. eCollection 2023 https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2023.1342817/full
PUBLICATIES 2022
1. van den Bosch A, Fransen N, Mason M, Rozemuller AJ, Teunissen C, Smolders J, Huitinga I. Neurofilament Light Chain Levels in Multiple Sclerosis Correlate With Lesions Containing Foamy Macrophages and With Acute Axonal Damage. Neurol Neuroimmunol Neuroinflamm. 2022 Mar 3;9(3):e1154. https://nn.neurology.org/content/9/3/e1154.long
2. Bruijstens AL, Molenaar S, Wong YYM, Kraaij R, Neuteboom RF. Gut microbiota analysis in pediatric-onset multiple sclerosis compared to pediatric monophasic demyelinating syndromes and pediatric controls. Eur J Neurol. 2022 Oct 9. doi: 10.1111/ene.15594. Online ahead of print. https://onlinelibrary.wiley.com/doi/full/10.1111/ene.15594
3. Cappelle S, Pareto D, SunaertS, Smets I, Laenen A, Dubois B, Demaerel Ph. 3T1w/FLAIR ratio standardization as a myelin marker in MS patients. Neuroimage Clin. 2022;36:103248. https://www.sciencedirect.com/science/article/pii/S2213158222003138?via%3Dihub
4. Dohrn MF, Rebelo AP, Srivastava S, Cappuccio G, Smigiel R, Malhotra A, Basel D, van de Laar I, Neuteboom RF, Aarts-Tesselaar C, Mahida S, Brunetti-Pierri N, Taft RJ, Züchner S De Novo ATP1A1 Variants in an Early-Onset Complex Neurodevelopmental Syndrome. Neurology. 2022;98(11):440-445. https://n.neurology.org/content/98/11/440.long
5. Helfferich J, de Lange MM, Benschop KS, Jacobs BC, Van Leer-Buter CC, Meijer A, Bakker DP, de Bie E, Braakman HM, Brandsma R, Neuteboom RF, Niks EH, Niermeijer JM, Roelfsema V, Schoenmaker N, Sie LT, Niesters HG, Brouwer OF, Te Wierik MJ. Epidemiology of acute flaccid myelitis in children in the Netherlands, 2014 to 2019. Euro Surveill. 2022 Oct;27(42):2200157. https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2022.27.42.2200157
6. Koetzier S, van Langelaar J, Melief MJ, wierenga-Wolf AF, Corsten CEA, Blok KM, Hoeks C, Broux B, Wokke B, van Luijn MM, Smolders J. distinct effector programs of brain-homing CD8+ T cells in multiple sclerosis. Cells 2022;11(10):1634. https://www.mdpi.com/2073-4409/11/10/1634
7. Koetzier SC, van Langelaar J, Wierenga-Wolf AF, Melief MJ, Pol K, Musters S, Lubberts E, Dik WA, Smolders J, van Luijn MM. Improving glucocorticoid sensitivity of brain-homing CD4 + T helper cells by steroid hormone crosstalk. Frontiers Immunol 2022;13:893702. https://www.frontiersin.org/articles/10.3389/fimmu.2022.893702/full
8. de Mol CL, Neuteboom RF, Jansen PR, White T. Response: No evidence for association between polygenic risk for multiple sclerosis and MRI phenotypes in approximately 30,000 healthy adult UK Biobank participants. Mult Scler. 2022;28(10):1658-9. https://journals.sagepub.com/doi/10.1177/13524585221079044
9. Rijvers L, van Langelaar J, Bogers L, Melief MJ, Koetzier SC, Blok KM, Wierenga-Wolf AF, de Vries HE, Rip J, Corneth OB, Hendriks RW, Grenningloh R, Boschert U, Smolders J, van Luijn MM. Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinib. JCI Insight. 2022 Aug 22;7(16):e160909. https://insight.jci.org/articles/view/160909
10. Smolders J, van Luijn MM, Hsiao CC, Hamann J. T-cell surveillance of the human brain in health and multiple sclerosis. Semin Immunopathol. 2022 Nov;44(6):855-867. https://link.springer.com/article/10.1007/s00281-022-00926-8
11. Smolders J, Hamann J. Programmed Cell Death Protein 1–Positive CD8+ T Cells in Multiple Sclerosis Exhausted Fighters or Peacekeepers. Neurol Neuroimmunol Neuroinflamm. 2022;9(4):e1173. https://nn.neurology.org/content/9/4/e1173.long
12. Tseng LA, Teela L, Janssen MC, Bok LA, Willemsen MAAP, Neuteboom RF, Haverman L, Gospe SM Jr, Coughlin CR, van Karnebeek CDM. Pyridoxine-dependent epilepsy (PDE-ALDH7A1) in adulthood: A Dutch pilot study exploring clinical and patient-reported outcomes. Mol Genet Metab Rep. 2022;31:100853. https://www.sciencedirect.com/science/article/pii/S2214426922000131?via%3Dihub
13. Versteegh MM, Huygens SA, Wokke BHA, Smolders J. Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple Sclerosis. Value Health. 2022 Jun;25(6):984-991. https://www.sciencedirect.com/science/article/pii/S1098301521031946?via%3Dihub
14. Willekens BMP, Bruijstens AL, Neuteboom R, Smolders J, Wokke BHA. MOGAD: MOG antibody associated disease. Tijdschr neurol neurochi 2022;123(8):354-60. https://www.tnnonline.nl/journal-article/mogad-mog-antistof-gerelateerde-ziekte/

PUBLICATIES 2021
1. Aalbers MW, Groen RJM, Appelman APA, Heersema TDJ, Wokke BHA, Oterdoom DLM. Spinal cord  ischaemia related to disc herniation: case report and a review of the literature. International medical case reports journal. 2021 June;14:429-433
2. de Mol CL, Bruijstens AL, Jansen PR, Dremmen M, Wong Y, van der Lugt A, White T, Neuteboom RF. Prevalence of radiologically isolated syndrome in a pediatric population-based cohort: A longitudinal description of a rare diagnosis. Mult Scler. 2021 Jan 22:1352458521989220.
3. Den Dunnen J, Mes L, Hoepel W, Smolders J. Multiple sclerosis: why we should focus on both sides of the antibody. Neural Regeneration Research 2021;16:2422-4.
4. Drop BRH, Zemel D, Wokke BHA, van Oosten BW, Dik S, Martins Jarnalo CO, Westerweel PE, de Beukelaar JWK. Diffuse alveolar hemorrhage as an early complication of alemtuzumab treatment: A case report of a multiple sclerosis patient and an overview of 14 cases. Mult Scler Relat Disord 2021;47:102614.
5. Fransen N, de Jong BA, Heß K, Kuhlmann T, Vincenten MCJ, Hamann J, Huitinga I, Smolders J. Absence of B cells in brainstem and white matter lesions associates with less severe disease and absence of oligoclonal bands in MS. Neurology Neuroimmunology & Neuroinflammation 2021;8:e995.
6. Ghedri A, Hintzen RQ, Wokke BHA, Pruissen DMO; Snelle diagnostiek en behandeling essentieel bij neuromyelitis optica spectrum disorder. Tijdschr neurol neurochir 2020;1221(4):171-5
7. Helfferich J, Bruijstens AL, Wong YYM, Danielle van Pelt E, Boon M, Neuteboom RF; Dutch Study Group for Pediatric Multiple Sclerosis and Acute Disseminated Encephalomyelitis. Prognostic factors for relapse and outcome in pediatric acute transverse myelitis. Brain Dev. 2021;43:626-636.
8. Hsiao CC, Fransen NL, van den Bosch AMR, Brandwijk KIM, Hamann J, Smolders J. White matter lesions in multiple sclerosis are enriched for CD20dim CD8+ tissue-resident memory T cells. European Journal of Immunology 2021;51:483-6..
9. Hsiao CC, Sankowski R, Prinz M, Smolders J, Huitinga I, Hamann J. GPCRomics of homeostatic and disease-associated human microglia. Frontiers in Immunology 2021, Frontiers in Immunology 2021;12:674189.
10. Janssen M, Rijvers L, Koetzier SC, Wierenga-Wolf AF, Melief MJ, van Langelaar J, Runia TF, de Groot CJM, Neuteboom R, Smolders J, van Luijn MM. Pregnancy-induced effects on memory B-cell development in multiple sclerosis. Scientific Reports 2021;11:12126.
11. Koetzier SC, Neuteboom RF, Wierenga-Wolf AF, Melief MJ, de Mol CL, van Rijswijk A, Dik WA, Broux B, van der Wal R, van den Berg SAA, Smolders J, van Luijn MM. Effector T helper cells are selectively controlled during pregnancy and related to a postpartum relapse in multiple sclerosis. Frontiers in Immunology 2021;12:642038.
12. Mimpen M, Muris AH, Rolf L, Gerlach O, Kuhle J, Hupperts R, Smolders J, Damoiseaux J. Prognostic value of NK cell/ T cell ratios for disease activity in multiple sclerosis. European Journal of Neurology 2021;28:901-9.
13. Mimpen M, Rolf L, Muris AH, Gerlach O, Poelmans G, Hupperts R, Smolders J, Damoiseaux J. NK/T cell ratio’s associate with IL-2 receptor alpha chain expression and shedding in multiple sclerosis. Journal of Neuroimmunology 2021;343:577499.
14. Smolders J, de Beer JJA, Frequin STFM, Harrison K, van Hoeve BJA , Hoitsma E, Hoogervorst ELJ, Killestein J, Lenderink AW, Moraal B, Mostert J, Siepman TAM, Witte DT, de Jong BA. Ziektemodulerende behandeling van mutiple sclerose bij volwassenen: Addendum bij de richtlijn multiple sclerose. Tijdschr Neurol Neurochir 2021;122:17-21.
15. Smolders J, Fransen NL, Huitinga I, Hamann J. Reply: Tissue-resident CD8+ memory T cells in multiple sclerosis. Brain 2021;144:e8.
16. Smolders J, Hiller A, Camu W. Editorial: Vitamin D in Neurological Diseases: From Pathophysiology to Therapy. Front Neurol. 2021 Mar 9;12:614900.
17. Smolders J, van den Ouweland J, Geven C, Prickkers P, Kox M. Vitamin D deficiency in COVID-19: mixing up cause and consequence. Metabolism, 2021;115;154434.
18. Van den Berg R, Broeders M, Wokke BHA, Thiadens AAHJ, Asseldonk JT, Titulaer. Syndorom van SUSAC: visusstoornis, doofheid en encefalopathie. Tijdschr neurol neurochir 2020;121(1):24-30
19. van Langelaar J, Wierenga-Wolf AF, Samijn JPA, Luijks CJM, Siepman TA, van Doorn PA, Bell A, van Zelm MC, Smolders J, van Luijn MM. The association of Epstein-Barr virus infection with CXCR3+ B-cell development in multiple sclerosis: impact of immunotherapies. European Journal of Immunology 2021;51:626-33.
20. de Mol CL, Looman KIM, van Luijn MM, Kreft KL, Jansen PR, van Zelm MC, Smolders J, White TJH, Moll HA, Neuteboom RF.T cell composition and polygenic multiple sclerosis risk: A population-based study in children. Eur J Neurol. 2021 Jul 12. doi: 10.1111/ene.15019.
21. Mimpen M , Damoiseaux J, van Doorn W, Rolf L, Muris AH, Hupperts R, van Luijn MM, Gerlach O, Smolders J. Proportions of circulating transitional B cells associate with MRI activity in interferon beta-treated multiple sclerosis patients. J Neuroimmunol 2021;358:577664.
22. de Mol CL, Neuteboom RF, Jansen PR, White T. White matter microstructural differences in children and genetic risk for multiple sclerosis: A population-based study. Mult Scler 2021, doi: 10.1177/13524585211034826.
23. Nosadini M, Thomas T, Eyre M, Anlar B, Armangue T, Benseler SM, Cellucci T, Deiva K, Gallentine W, Gombolay G, Gorman MP, Hacohen Y, Jiang Y, Lim BC, Muscal E, Ndondo A, Neuteboom R, Rostásy K, Sakuma H, Sharma S, Tenembaum SN, Van Mater HA, Wells E, Wickstrom R, Yeshokumar AK, Irani SR, Dalmau J, Lim M, Dale RC. International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurol Neuroimmunol Neuroinflamm 2021;8(5):e1052.
24. Mimpen M, Rolf L, Poelmans G, van den Ouweland J, Hupperts R, Damoiseaux J, Smolders J. Vitamin D related genetic polymorphisms affect serological response to high-dose vitamin D supplementation in multiple sclerosis. PLoS One. 2021 Dec 2;16(12):e0261097
25. Bastiaansen AEM, de Bruijn MAAM, Schuller SL, Martinez-Hernandez E, Brenner J, Paunovic M, Crijnen YS, Mulder MJHL, Schreurs MWJ, de Graaff E, Smitt PAE, Neuteboom RF, de Vries JM, Titulaer MJ. Anti-NMDAR Encephalitis in the Netherlands, Focusing on Late-Onset Patients and Antibody Test Accuracy. Neurol Neuroimmunol Neuroinflamm. 2021 Dec 22;9(2):e1127.
26. Nosadini M, Eyre M, Molteni E, Thomas T, Irani SR, Dalmau J, Dale RC, Lim M; International NMDAR Antibody Encephalitis Consensus Group, Anlar B, Armangue T, Benseler S, Cellucci T, Deiva K, Gallentine W, Gombolay G, Gorman MP, Hacohen Y, Jiang Y, Lim BC, Muscal E, Ndondo A, Neuteboom R, Rostásy K, Sakuma H, Sartori S, Sharma S, Tenembaum SN, Van Mater HA, Wells E, Wickstrom R, Yeshokumar AK. Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis. JAMA Neurol. 2021 Nov 1;78(11):1333-1344.

PUBLICATIES 2020
1. Armangue T, Capobianco M, de Chalus A, Laetitia G, Deiva K; E.U. paediatric MOG consortium. E.U. paediatric MOG consortium consensus: Part 3 – Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020 Nov;29:22-31. 
2. Baumann M, Bartels F, Finke C, Adamsbaum C, Hacohen Y, Rostásy K; E.U. paediatric MOG consortium. E.U. paediatric MOG consortium consensus: Part 2 – Neuroimaging features of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020 Nov;29:14-21.
3. Bruijstens AL, Blok KM, Smolders J, Wokke BH, Neuteboom RF. Pediatric MS patients with a primary progressive-like disease may still have relevant inflammatory activity and may benefit from regular MS treatment. Multiple Sclerosis Journal 2020;26:1962-4. 
4. Bruijstens AL, Breu M, Wendel EM, Wassmer E, Lim M, Neuteboom RF, Wickström R; E.U. paediatric MOG consortium. E.U. paediatric MOG consortium consensus: Part 4 – Outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020 Nov;29:32-40. 
5. Bruijstens AL, Lechner C, Flet-Berliac L, Deiva K, Neuteboom RF, Hemingway C, Wassmer E; E.U. paediatric MOG consortium. E.U. paediatric MOG consortium consensus: Part 1 – Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020 Nov;29:2-13.
6. Bruijstens AL, Wendel EM, Lechner C, Bartels F, Finke C, Breu M, Flet-Berliac L, de Chalus A, Adamsbaum C, Capobianco M, Laetitia G, Hacohen Y, Hemingway C, Wassmer E, Lim M, Baumann M, Wickström R, Armangue T, Rostasy K, Deiva K, Neuteboom RF. E.U. paediatric MOG consortium consensus: Part 5 – Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020 Nov;29:41-53. 
7. Bruijstens AL, Wong YYM, van Pelt DE, van der Linden PJE, Haasnoot GW, Hintzen RQ, Claas FHJ, Neuteboom RF, Wokke BHA. HLA association in MOG-IgG- and AQP4-IgG-related disorders of the CNS in the Dutch population. Neurol Neuroimmunol Neuroinflamm. 2020;7(3):e702. 
8. de Bruijn MAAM, Bruijstens AL, Bastiaansen AEM, van Sonderen A, Schreurs MWJ, Sillevis Smitt PAE, Hintzen RQ, Neuteboom RF, Titulaer MJ; CHANCE Study Group. Pediatric autoimmune encephalitis: Recognition and diagnosis. Neurol Neuroimmunol Neuroinflamm. 2020 Feb 11;7(3):e682.
9. de Mol CL, Jansen PR, Muetzel RL, Knol MJ, Adams HH, Jaddoe VW, Vernooij MW, Hintzen RQ, White TJ, Neuteboom RF. Polygenic Multiple Sclerosis Risk and Population-Based Childhood Brain Imaging. Ann Neurol. 2020 May;87(5):774-787. 
10. de Mol CL, Wong Y, van Pelt ED, Wokke B, Siepman T, Neuteboom RF, Hamann D, Hintzen RQ. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler 2020;26:806-814.
11. Doerga PN, Rijken BFM, Bredero-Boelhouwer H, Joosten KFM, Neuteboom RF, Tasker RC, Dremmen MHG, Lequin MH, van Veelen MLC, Mathijssen IMJ. Neurological deficits are present in syndromic craniosynostosis patients with and without tonsillar herniation. Eur J Paediatr Neurol. 2020 Sep;28:120-125. 
12. Fransen N, Hsiao CC, van der Poel M, Engelenburg HJ, Verdaasdonk K, Vincenten MCJ, Remmerswaal EBM, Kuhlmann T, Mason MRJ, Hamann J, Smolders J, Huitinga I. Tissue resident memory T cells invade the brain parenchyma in chronic multiple sclerosis white matter lesions. Brain 2020;143:1714-30.
13. Fritz D, Timmermans WMC, van Laar JAM, van Hagen PM, Siepman TAM, van de Beek D, Brouwer MC. Infliximab treatment in pathology-confirmed neurosarcoidosis. Neurol Neuroimmunol Neuroinflamm. 2020;7:e847.
14. Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383(6):546-557. 
15. Janssen M, Bruijstens AL, van Langelaar J, Wong Y, Wierenga-Wolf AF, Melief MJ, Rijvers L, van Pelt ED, Smolders J, Wokke BH, van Luijn MM. Naive B cells in neuromyelitis optica spectrum disorders: impact of steroid use and relapses. Brain Comm 2020;2:fcaa197. 
16. Koetzier SC, van Langelaar J, Blok KM, van den Bosch TPP, Wierenga-Wolf AF, Melief MJ, Pol K, Siepman TA, Verjans GMGM, Smolders J, Lubberts E, de Vries HE, van Luijn MM. Brain-homing CD4+ T cells display glucocorticoid-resistant features in multiple sclerosis. Neurology Neuroimmunology & Neuroinflammation 2020;7:e894. 
17. Mescheriakova JY, van Nierop GP, van der Eijk AA, Kreft KL, Hintzen RQ. EBNA-1 titer gradient in families with multiple sclerosis indicates a genetic contribution. Neurol Neuroimmunol Neuroinflamm. 2020 Aug 13;7(6):e872.
18. Mimpen M, Smolders J, Hupperts R, Damoiseaux J. Natural Killer Cells in Multiple Sclerosis, a review. Immunology Letters 2020;222:1-11. 
19. Muñoz-Lopetegi A, de Bruijn MAAM, Boukhrissi S, Bastiaansen AEM, Nagtzaam MMP, Hulsenboom ESP, Boon AJW, Neuteboom RF, de Vries JM, Sillevis Smitt PAE, Schreurs MWJ, Titulaer MJ. Neurologic syndromes related to anti-GAD65: Clinical and serologic response to treatment. Neurol Neuroimmunol Neuroinflamm. 2020 Mar 2;7(3):e696.
20. Neuteboom RF, Deiva K, Rostasy K. Editorial on EJPN focus section on E.U. paediatric MOG consortium consensus statements. Eur J Paediatr Neurol. 2020 Nov;29:1.
21. Neuteboom RF. Myelin-oligodendrocyte-glycoprotein antibody associated disorders (MOGAD): More than meets the eye. Eur J Paediatr Neurol. 2020 Jul;27:2. 
22. Pak N, Selehnia A, Hunfeld MAW, Lequin MH, Neuteboom RF, de Vries ACH, Kroon AA, Dremmen MHG. Atypical neuroimaging characteristics of hemophagocytic lymphohistiocytosis in infants: a case series of hemorrhagic brain lesions in the deep grey matter. Neuroradiology. 2021 Feb;63(2):285-288. 
23. Paolilo RB, Deiva K, Neuteboom R, Rostásy K, Lim M. Acute Disseminated Encephalomyelitis: Current Perspectives. Children (Basel). 2020 Nov 3;7(11):210. 
24. Paolilo RB, Hacohen Y, Yazbeck E, Armangue T, Bruijstens A, Lechner C, Apostolos-Pereira SL, Martynenko Y, Breu M, de Medeiros Rimkus C, Wassmer E, Baumann M, Papetti L, Capobianco M, Kornek B, Rostásy K, da Paz JA, Ciccarelli O, Lim M, Saiz A, Neuteboom R, Marignier R, Hemingway C, Sato DK, Deiva K. Treatment and outcome of aquaporin-4 antibody-positive NMOSD: A multinational pediatric study. Neurol Neuroimmunol Neuroinflamm. 2020 Jul 30;7(5):e837.
25. Rijvers L, Melief MJ, van Langelaar J, van der Vuurst de Vries RM, Wierenga-Wolf AF, Koetzier SC, Priatel JJ, Jorritsma T, van Ham SM, Hintzen RQ, van Luijn MM. The Role of Autoimmunity-Related Gene CLEC16A in the B Cell Receptor-Mediated HLA Class II Pathway. J Immunol. 2020 Aug 15;205(4):945-956. 
26. Smolders J, Fransen NL, Hsiao CC, Hamann J, Huitinga I. Perivascular tissue resident memory T cells as therapeutic target in multiple sclerosis. Expert Reviews in Neurotherapeutics, 2020;20:835-48. 
27. Van Langelaar J, Rijvers L, Smolders J, van Luijn MM. B and T cells driving multiple sclerosis: identity, mechanisms and potential triggers. Frontiers in Immunology 2020;11:760. 
28. Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, Pardo S, Gornall M, Cicconi S, Brandt A, Berek K, Berger T, Jelcic I, Gombolay G, Oliveira LM, Callegaro D, Kaneko K, Misu T, Capobianco M, Gibbons E, Karthikeayan V, Brochet B, Audoin B, Mathey G, Laplaud D, Thouvenot E, Cohen M, Tourbah A, Maillart E, Ciron J, Deschamps R, Biotti D, Rostasy K, Neuteboom R, Hemingway C, Forsyth R, Matiello M, Webb S, Hunt D, Murray K, Hacohen Y, Lim M, Leite MI, Palace J, Solomon T, Lutterotti A, Fujihara K, Nakashima I, Bennett JL, Pandit L, Chitnis T, Weinshenker BG, Wildemann B, Sato DK, Kim SH, Huda S, Kim HJ, Reindl M, Levy M, Jarius S, Tenembaum S, Paul F, Pittock S, Marignier R, Jacob A. Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. Mult Scler Relat Disord. 2020;44:102251. 
29. Whittam DH, Karthikeayan V, Gibbons E, Kneen R, Chandratre S, Ciccarelli O, Hacohen Y, de Seze J, Deiva K, Hintzen RQ, Wildemann B, Jarius S, Kleiter I, Rostasy K, Huppke P, Hemmer B, Paul F, Aktas O, Pröbstel AK, Arrambide G, Tintore M, Amato MP, Nosadini M, Mancardi MM, Capobianco M, Illes Z, Siva A, Altintas A, Akman-Demir G, Pandit L, Apiwattankul M, Hor JY, Viswanathan S, Qiu W, Kim HJ, Nakashima I, Fujihara K, Ramanathan S, Dale RC, Boggild M, Broadley S, Lana-Peixoto MA, Sato DK, Tenembaum S, Cabre P, Wingerchuk DM, Weinshenker BG, Greenberg B, Matiello M, Klawiter EC, Bennett JL, Wallach AI, Kister I, Banwell BL, Traboulsee A, Pohl D, Palace J, Leite MI, Levy M, Marignier R, Solomon T, Lim M, Huda S, Jacob A. Treatment of MOG antibody associated disorders: results of an international survey. J Neurol. 2020;267:3565-3577.